Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Cybin公司開始進行第三階段試驗，大力押注CYB003治療抑鬱症
Cybin Inc. (AMEX:CYBN) has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead candidate, CYB003, for treating Major Depressive Disorder (MDD) in a move that comes after three years of development.
Cybin Inc.（美交所:CYBN）推出了其第三階段的關鍵項目PARADIGm，旨在測試其主要候選藥物CYB003治療重性抑鬱障礙（MDD）的療效。這一舉措是在經過三年發展之後進行的。
"Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone," said Doug Drysdale, CEO of Cybin.
「在爲CYB003提交新藥申請僅僅三年後，啓動我們的第三階段項目是一個真正重要且令人滿意的里程碑，」Cybin的CEO Doug Drysdale表示。
The design of the PARADIGM program, according to Drysdale, has been shaped by a collaborative process with the Food and Drug Administration (FDA), taking into account the challenges faced by other...
根據Drysdale的說法，PARADIGm項目的設計是通過與...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間